![Mark Bachleda](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Bachleda
Directeur/Membre du Conseil chez
LYELL IMMUNOPHARMA, INC.
Fortune : - $ au 30/06/2026
Profil
Mark J.
Bachleda is currently Chief Executive Officer & Director at Eyconis, Inc. since 2024 and Independent Director at Lyell Immunopharma, Inc. starting in 2025.
Former positions include Vice President at Bristol Myers Squibb Co., Chief Commercial Officer at Galera Therapeutics, Inc. from 2021 to 2023, and Vice President-Sales & Account Management at Juno Therapeutics, Inc. Education includes an MBA from the University of California, Berkeley and a doctorate from the University of Illinois.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Mark Bachleda
| Sociétés | Poste | Début |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Directeur/Membre du Conseil | 09/06/2025 |
Anciens postes connus de Mark Bachleda
| Sociétés | Poste | Fin |
|---|---|---|
| GALERA THERAPEUTICS, INC. | Corporate Officer/Principal | 09/08/2023 |
| JUNO THERAPEUTICS INC | Sales & Marketing | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Mark Bachleda
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
23
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Galera Therapeutics, Inc.
 Galera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs to reduce normal tissue toxicity from radiotherapy | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
